Low-dose methotrexate in rheumatoid arthritis: effect and tolerance. An open trial and a double-blind randomized study

Scand J Rheumatol. 1986;15(2):97-102. doi: 10.3109/03009748609102072.


Weekly low-dose Mtx may be considered the preferred drug for the treatment of patients with severe, progressive RA resistant to conventional therapy. The drug is sufficiently safe, provided contra-indications are considered and treatment is carefully supervised. Controlled long-term prospective studies are needed in order to determine whether the drug demonstrably retards progression of the erosions, and to guard against untoward long-term adverse reactions.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Arthritis, Rheumatoid / drug therapy*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Humans
  • Methotrexate / administration & dosage*
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use
  • Middle Aged
  • Prospective Studies


  • Methotrexate